Design Therapeutics (DSGN) Stock Price, News & Analysis

Company Overview

Design Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of gene therapies for rare neuromuscular disorders. The company’s proprietary platform leverages adeno‐associated virus (AAV) vectors to deliver therapeutic genes or gene regulators to target muscle tissue. Design Therapeutics’ lead program, DT-010, is designed to address the underlying cause of Duchenne and Becker muscular dystrophy by restoring functional dystrophin protein expression in skeletal and cardiac muscle cells.

Beyond Duchenne and Becker muscular dystrophy, Design Therapeutics is advancing additional pipeline candidates aimed at other genetic muscle diseases. A second program focuses on facioscapulohumeral muscular dystrophy (FSHD) by employing an AAV‐based strategy to silence the DUX4 gene implicated in disease progression. The company is also exploring treatments for myotonic dystrophy type 1 (DM1), applying the same vector technology to deliver oligonucleotide or gene editing payloads that modulate pathogenic RNA repeats.

Founded in 2020 and headquartered in Boston, Design Therapeutics has rapidly assembled a team of experts in gene therapy, neuromuscular biology and clinical development. Chief Executive Officer Michel Perron, Ph.D., brings more than two decades of experience in rare disease research and biopharmaceutical leadership. The company’s scientific advisory board features key opinion leaders in neuromuscular disorders, supporting the design and execution of clinical trials across multiple patient populations.

Design Therapeutics conducts its research and early‐stage clinical studies in the United States, with plans to expand global trial sites to Europe and Asia as its development programs progress. Through collaborations with academic centers and patient advocacy groups, the company aims to accelerate enrollment, gather comprehensive natural history data and ensure broad access to investigational therapies. Its long‐term strategy encompasses both in‐house manufacturing scale-up and partnerships with contract development and manufacturing organizations to support future commercialization efforts.

Key Stats

• Today's Range: $3.95 to $4.34
• 50-Day Range: $3.21 to $4.17
• 52-Week Range: $2.60 to $7.77
• Volume: 90,613 shs
• Average Volume: 176,830 shs
• Market Capitalization: $228.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Design Therapeutics Stock Analysis - MarketRank™

Design Therapeutics scored higher than 9% of companies evaluated by MarketBeat, and ranked 903rd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Design Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Design Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Design Therapeutics are expected to decrease in the coming year, from ($0.91) to ($1.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Design Therapeutics is -4.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Design Therapeutics is -4.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Design Therapeutics has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.73% of the float of Design Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Design Therapeutics has a short interest ratio ("days to cover") of 30.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Design Therapeutics has recently decreased by 0.82%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Design Therapeutics does not currently pay a dividend.

Dividend Growth

Design Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.73% of the float of Design Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Design Therapeutics has a short interest ratio ("days to cover") of 30.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Design Therapeutics has recently decreased by 0.82%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Design Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Design Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Design Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.20% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

56.64% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DSGN Stock Analysis - Frequently Asked Questions

How have DSGN shares performed this year?

Design Therapeutics' stock was trading at $6.17 on January 1st, 2025. Since then, DSGN stock has decreased by 34.8% and is now trading at $4.02.

How were Design Therapeutics' earnings last quarter?

Design Therapeutics, Inc. (NASDAQ:DSGN) released its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.03.

When did Design Therapeutics IPO?

Design Therapeutics (DSGN) raised $228 million in an initial public offering on Friday, March 26th 2021. The company issued 12,000,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Who are Design Therapeutics' major shareholders?

Top institutional investors of Design Therapeutics include Assenagon Asset Management S.A. (0.05%). Insiders that own company stock include Sr One Capital Fund I Aggregat, Simeon George, Rodney W Lappe, Joao Md Siffert, John P Schmid, Deepa Prasad and Arsani William.
View institutional ownership trends.

How do I buy shares of Design Therapeutics?

Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Design Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Design Therapeutics investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/17/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DSGN
• CIK: 1807120
• Web: www.designtx.com
• Phone: 858-293-4900
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Design Therapeutics: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: -0.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$49.59 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -22.85%
• Return on Assets: -22.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 28.37
• Quick Ratio: 28.37

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.28 per share
• Price / Book: 0.94

Miscellaneous

• Outstanding Shares: 56,770,000
• Free Float: 39,057,000
• Market Cap: $228.22 million
• Optionable: Optionable
• Beta: 1.56